Advances on CD8+ Tregs and their potential in transplantation

Although CD8+ Tregs have been in the last 20 years more studied since evidences of their role in tolerance as been demonstrated in transplantation, autoimmune diseases and cancer, their characteristics are still controversial. In this review, we will focus on recent advances on CD8+ Tregs and description of a role for CD8+ Tregs in tolerance in both solid organ transplantation and GVHD and their potential for clinical trials. Corresponding authors: Dr. Carole Guillonneau and Dr. Ignacio Anegon, Centre de Recherche en Transplantation et Immunologie INSERM 1064-ITUN, 30 Bd. Jean Monnet, 44093, Nantes Cedex 01, France. Phone: (+33) 2 40087410, Fax: (+33) 2 40087411. E-mail addresses: carole.guillonneau@univ-nantes.fr and ignacio.anegon@univ-nantes.fr The authors declare that they have no conflict of interest. Authorship Carole Guillonneau participated in the writing of the paper. Ignacio Anegon participated in the writing of the paper. Séverine Bézie participated in the writing of the paper. Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.

https://ift.tt/2KaEc0N